PM360

FEBRUARY 1, 2024

Embarking on the journey from product development to market success in the biopharma industry is no small feat. The landscape is highly competitive with new prescription medications launching worldwide each year. However, this journey is fraught with challenges as revealed by an in-depth analysis.

Biopharma 59

Biopharma Competition Prescription Marketing 59

PM360

APRIL 22, 2024

In this issue, we take a closer look on the importance of patient education to Healthcare Professionals and navigating the challenges that arise. With an ever- increasing demand for their time and attention, it is more difficult than ever for biopharma representatives to convey their message to the physician audience.

Education 59

Education Physicians Healthcare Healthcare 59

Clarivate

DECEMBER 6, 2022

In a fiercely competitive U.S. healthcare provision landscape, integrated delivery networks, or IDNs, are differentiating their offerings by adding outpatient treatment centers, pursuing National Cancer Institute designations and investing in value-based care. Christopher Silva, Senior Healthcare Research Analyst.

Networking 52

Networking Healthcare Healthcare Competition 52

PM360

NOVEMBER 12, 2023

While the global biopharma industry retains its huge dependence on the U.S. This should, at least in theory, make them an appealing target for biopharma companies looking to expand beyond the hugely competitive markets of the U.S., market, emerging markets present great opportunities for biotech and pharmaceutical companies.

Marketing 59

Marketing Biopharma Government Pharma 59

Clarivate

MAY 8, 2024

As companies face the prospect of major revenue challenges over the next few years, securing inorganic growth through strategic alliances is increasingly attractive. As a result, 2023 saw an upsurge in merger and acquisition (M&A) and deal activity. A prime example of strategic spending is Merck & Co./MSD,

Pharma 59

Pharma Biopharma Prospecting Competition 59

Clarivate

OCTOBER 7, 2021

As part of our Drugs to Watch series, which reviews therapies expected to have significant impact on healthcare markets, Clarivate oncology experts sifted through the more than 2,800 abstracts that were accepted for presentation at the ESMO 2021 Virtual Conference and selected their top picks. Abstract LBA52. Abstract 944P.

Patients 91

Patients Safety Marketing Physicians 91

Pharmaceutical Technology

MARCH 21, 2023

Vetter Pharma-Fertigung GmbH & Co KG is contracted for the parenteral manufacture and packaging for the vascular endothelial growth factor (VEGF) inhibitor, while Biogen and KBI Biopharma are producing the biologic API. Baxter Biopharma Solutions is contracted for the parenteral manufacture and packaging of Enhertu.

Manufacturing 59

Manufacturing Pharmaceutical Biopharma FDA 59